Open Interest and Volume Dynamics
The latest data reveals that Aurobindo Pharma’s open interest (OI) in derivatives rose sharply by 6,192 contracts, a 13.37% increase from the previous tally of 46,301 to 52,493. This surge in OI is accompanied by a daily volume of 12,813 contracts, indicating heightened trading activity and fresh positions being established rather than merely unwinding existing ones.
The futures segment alone accounts for a substantial value of ₹51,723.97 lakhs, while options contribute an even larger notional value of approximately ₹5,501 crores. The combined derivatives turnover stands at ₹52,424.03 lakhs, underscoring the significant liquidity and interest in Aurobindo Pharma’s contracts.
Such a pronounced increase in open interest, coupled with strong volume, typically suggests that market participants are positioning for a sustained move in the underlying stock, rather than short-term volatility. This is particularly relevant given the stock’s recent price action and technical setup.
Price Performance and Technical Strength
Aurobindo Pharma’s share price has outperformed its Pharmaceuticals & Biotechnology sector peers, registering a 1.37% gain on the day compared to the sector’s 0.71% and the Sensex’s 0.43%. The stock’s upward momentum is further validated by its trading above all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — signalling a strong bullish trend across multiple timeframes.
Notably, the stock achieved a new 52-week high of ₹1,530 on 19 May 2026, reflecting sustained buying interest. However, delivery volumes have declined by 26.51% to 5.02 lakh shares on 18 May, suggesting that while short-term speculative activity is robust, longer-term investor participation has moderated slightly.
This divergence between derivatives activity and delivery volumes may indicate that traders are increasingly relying on futures and options to express their market views, possibly due to leverage advantages or hedging strategies.
Only 1% make it here. This Large Cap from the Gems, Jewellery And Watches sector passed our rigorous filters with flying colors. Be among the first few to spot this gem!
- - Highest rated stock selection
- - Multi-parameter screening cleared
- - Large Cap quality pick
Market Positioning and Directional Bets
The surge in open interest alongside rising prices and volume suggests that traders are predominantly taking bullish positions on Aurobindo Pharma. The increase in futures open interest by over 13% indicates fresh long positions or rollovers of existing longs, reflecting optimism about the company’s near-term prospects.
Options market data, with a notional value exceeding ₹5,500 crores, also points to active call option buying, which typically signals expectations of further upside. The stock’s underlying value at ₹1,522 aligns closely with its recent highs, reinforcing the view that market participants anticipate continued strength.
Given the pharmaceutical sector’s defensive qualities and Aurobindo Pharma’s solid fundamentals, including a Market Mojo score of 72.0 and an upgraded Mojo Grade from Hold to Buy as of 24 March 2026, investors appear confident in the company’s growth trajectory and resilience amid broader market fluctuations.
Liquidity and Trading Considerations
Liquidity remains ample for sizeable trades, with the stock’s average traded value supporting a trade size of approximately ₹3.76 crores based on 2% of the 5-day average. This ensures that institutional and retail participants can execute large orders without significant market impact, further encouraging active participation in derivatives.
However, the noted decline in delivery volumes warrants cautious monitoring, as it may reflect a temporary pullback in long-term investor conviction or profit-booking after recent gains. Traders should weigh these factors alongside technical signals and sectoral trends when formulating strategies.
Thinking about Aurobindo Pharma Ltd.? Our real-time Verdict report breaks down everything – from financial health and peer comparison to technical signals and fair valuation for this mid-cap stock!
- - Real-time Verdict available
- - Financial health breakdown
- - Fair valuation calculated
Outlook and Investor Takeaways
In summary, Aurobindo Pharma’s recent open interest surge in derivatives, combined with its strong price performance and technical positioning, signals a bullish market consensus. The upgrade in its Mojo Grade to Buy and a solid Mojo Score of 72.0 further reinforce the stock’s appeal within the Pharmaceuticals & Biotechnology sector.
Investors should consider the implications of increased derivatives activity as a sign of growing confidence, while remaining mindful of the slight dip in delivery volumes. The stock’s ability to sustain above key moving averages and maintain liquidity supports continued interest from both traders and longer-term investors.
As the pharmaceutical sector continues to attract attention for its defensive qualities and growth potential, Aurobindo Pharma stands out as a mid-cap contender with favourable market positioning and robust investor interest.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
